Healthcare New Lows: VIVUS (NASDAQ:VVUS), Antares Pharma (NASDAQ:ATRS), Ignyta Inc (NASDAQ:RXDX), MELA Sciences Inc (NASDAQ:MELA)

Posted by on Apr 09, 2014

VIVUS, Inc. (NASDAQ:VVUS) announced that J. Martin Carroll, Mark B. Logan and Robert N. Wilson have decided not to stand for re-election when their terms expire at the Annual Meeting of Stockholders, to be held on June 20, 2014. VIVUS, Inc. (NASDAQ:VVUS) shares after opening at $5.10 moved to $5.20 on last trade day and at the end of the day closed at $4.99. Company price to sales ratio in past twelve months was calculated as 6.36 and price to cash ratio as 1.50. VIVUS, Inc. (NASDAQ:VVUS) showed a negative weekly performance of -17.38%.

TheStreet downgraded shares of Antares Pharma (NASDAQ:ATRS) from a hold rating to a sell rating in a research note released on Monday morning, Stock Ratings Network reports. Antares Pharma Inc (NASDAQ:ATRS) shares fell -1.51% in last trading session and ended the day on $3.27. ATRS return on equity ratio is recorded as -26.70% and its return on assets is -23.10%.  Antares Pharma Inc (NASDAQ:ATRS) yearly performance is -6.84%.

The Board of Directors (the “Board”) of Ignyta, Inc. (NASDAQ:RXDX) adopted the Ignyta, Inc. Employment Inducement Incentive Award Plan (the “Inducement Plan”). The Inducement Plan provides for the grant of equity-based awards in the form of non-qualified stock options, restricted stock awards, restricted stock unit awards, dividend equivalent awards, stock payment awards and stock appreciation rights. The Inducement Plan was adopted by the Board without stockholder approval pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. Ignyta Inc (NASDAQ:RXDX) shares moved down -5.78% in last trading session and was closed at $ 6.68 while trading in range of $6.36 – $7.39 – Ignyta Inc (NASDAQ:RXDX) year to date (YTD) performance is -66.60%.

MELA Sciences, Inc  (NASDAQ:MELA) entered into an agreement (the “Agreement”) granting to Broadfin Capital, LLC, in connection with its purchase of the Company’s Series A Convertible Preferred Stock and warrants to purchase common stock, the right to designate one director to the Company’s Board of Directors, so as long as it retains 30% of its investment in the Preferred Stock (or the shares of common stock underlying the Preferred Stock) or holds any warrants. On March 31, 2014, the Company and Broadfin terminated this Agreement.  MELA Sciences Inc (NASDAQ:MELA) weekly performance is -14.29%. On last trading day company shares ended up $0.540.  MELA Sciences Inc (NASDAQ:MELA) distance from 50-day simple moving average (SMA50) is -22.01%. Analysts mean target price for the company is $1.00.

Leave a Reply

Your email address will not be published. Required fields are marked *